Dr. Jacqueline Corrigan-Curay, JD, MD, Acting Director for Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration | Official website
Dr. Jacqueline Corrigan-Curay, JD, MD, Acting Director for Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration | Official website
Congressman Brett Guthrie and Congressman Morgan Griffith have announced a legislative hearing focused on preserving access to timely and affordable care. The hearing, titled "Legislative Proposals to Maintain and Improve the Public Health Workforce, Rural Health, and Over-the-Counter Medicines," will take place on Wednesday, July 16, 2025, at 10:00 AM ET in the Rayburn House Office Building.
Chairman Guthrie and Chairman-Designate Griffith emphasized the importance of public health programs in enhancing healthcare for Americans. They highlighted the significance of initiatives like the Over-the-Counter Monograph Drug User Fee Program in ensuring patient access to safe over-the-counter products. "These vital public health programs play a critical role in improving health care for Americans," they said.
The hearing will be open to both the public and press, with a livestream available online. Questions regarding the hearing can be directed to Annabelle Huffman, while press inquiries should be addressed to Katie West.
Dr. Jacqueline Corrigan-Curay from the FDA's Center for Drug Evaluation and Research testified before the Subcommittee on Health about reauthorizing the Over-the-Counter Monograph Drug User Fee Program (OMUFA). She discussed OMUFA’s contributions to modernizing OTC drug regulation and its impact on safety and innovation.
Dr. Corrigan-Curay noted that OMUFA I funded infrastructure improvements, including hiring staff and developing IT systems. Looking ahead, OMUFA II aims for $206.8 million in revenue to support new full-time employees and enhance quality surveillance. Key priorities include improved facility vetting, compliance workshops, risk-based inspections, transparency through public dashboards, aligned fee deadlines, extended industry meetings, and advance notice for Advisory Committees.
She stressed that without reauthorization of OMUFA II, crucial updates could face significant delays. Dr. Corrigan-Curay concluded by urging timely reauthorization to maintain an effective OTC regulatory system.
Information from this article can be found here.
Alerts Sign-up